How to buy XORTX Therapeutics stock

XORTX Therapeutics, a company that develops therapies to inhibit the production of uric acid, has applied for listing on the Nasdaq.

XORTX Therapeutics stock price (NASDAQ: XRTX)

Use our graph to track the performance of XRTX stocks over time.

XORTX Therapeutics shares at a glance

• Key figures

Information last updated 2023-01-31.

Latest market close	$0.59
52-week range	$0.57 - $2.48
50-day moving average more info button	$0.82
200-day moving average more info button	$1.21
Wall St. target price	$9.03
PE ratio more info button	1.7848
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$0.33

Buy XORTX Therapeutics stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy XORTX Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

XORTX Therapeutics price performance over time

Historical closes compared with the close of $0.5931 from 2023-02-03

1 week (2023-01-27)	-3.40%
1 month (2023-01-04)	-31.91%
3 months (2022-11-04)	-25.96%
6 months (2022-08-04)	-58.23%

1 year (2022-02-04)	-61.98%
2 years (2021-02-04)	157.87%
3 years (2020-01-31)	N/A
5 years (2018-01-31)	N/A

Is XORTX Therapeutics stock undervalued or overvalued?

Valuing XORTX Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of XORTX Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

XORTX Therapeutics's P/E ratio

XORTX Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, XORTX Therapeutics shares trade at around 2x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

However, XORTX Therapeutics's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.

• Biogen (BIIB.US): 15.08
• Pfizer (PFE.US): 8.46
• Johnson-and-Johnson (JNJ.US): 24.51

XORTX Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-55%
Return on equity TTM	78.15%
Profit margin	0%
Book value	$0.82
Market capitalisation more info button	$8.5 million

TTM: trailing 12 months

XORTX Therapeutics share dividends

We're not expecting XORTX Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

• Pfizer (PFE.US) (3.77% forward annual dividend yield)
• Johnson-and-Johnson (JNJ.US) (2.69% forward annual dividend yield)

Have XORTX Therapeutics's shares ever split?

XORTX Therapeutics's shares were split on a 50:587 basis on 23 September 2021. So if you had owned 587 shares the day before before the split, the next day you'd have owned 50 shares. This wouldn't directly have changed the overall worth of your XORTX Therapeutics shares – just the quantity. However, indirectly, the new 1074% higher share price could have impacted the market appetite for XORTX Therapeutics shares which in turn could have impacted XORTX Therapeutics's share price.

XORTX Therapeutics share price volatility

Over the last 12 months, XORTX Therapeutics's shares have ranged in value from as little as $0.571 up to $2.48. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while XORTX Therapeutics's is 0.3168. This would suggest that XORTX Therapeutics's shares are less volatile than average (for this exchange).

To put XORTX Therapeutics's beta into context you can compare it against those of similar companies.

• Biogen (BIIB.US): 0.2117
• Pfizer (PFE.US): 0.6331
• Johnson-and-Johnson (JNJ.US): 0.5706

XORTX Therapeutics overview

XORTX Therapeutics Inc. , a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada. .

Frequently asked questions

What percentage of XORTX Therapeutics is owned by insiders or institutions?
Currently 3.737% of XORTX Therapeutics shares are held by insiders and 6.671% by institutions. When does the fiscal year end for XORTX Therapeutics?
XORTX Therapeutics's fiscal year ends in December. Where is XORTX Therapeutics based?
XORTX Therapeutics's address is: 421 ? 7th Avenue SW, Vancouver, BC, Canada, T2P 4K9 What is XORTX Therapeutics's ISIN number?
XORTX Therapeutics's international securities identification number is: CA98420Q2071